Business Context and Reporting Period
Company: OXIS International, Inc. (Note: Metadata referenced GT Biopharma, but filing content is for OXIS International, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2009
Business Overview: The Company focuses on the development of nutraceutical and therapeutic products related to oxidative stress, specifically L-Ergothioneine. In December 2008, the Company sold its assay business division (BioCheck) to Percipio Biosciences, Inc., receiving a $250,000 promissory note. The Company is a smaller reporting company with a significant accumulated deficit.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenue | $286,000 | $0 |
| Gross Profit | $112,000 | $0 |
| Net Loss | $(286,000) | $(1,094,000) |
| Loss Per Share (Basic/Diluted) | $(0.01) | $(0.02) |
| Cash and Cash Equivalents (End of Period) | $0 | $1,068,000 |
| Total Assets | $558,000 | $590,000 (Dec 31, 2008) |
| Total Current Liabilities | $4,524,000 | $4,270,000 (Dec 31, 2008) |
| Accumulated Deficit | $(75,140,000) | $(74,854,000) (Dec 31, 2008) |
Liquidity: The Company had zero cash on hand as of March 31, 2009. Net cash used in operating activities was $32,000 for the quarter. The Company has no available credit or bank financing.
Material Changes vs. Prior Period
- Revenue: Product revenue of $286,000 in Q1 2009 is attributed to the sale of the assay kit division in December 2008. The filing notes a decrease in product revenues compared to 2008 in the MD&A tables, but the Statement of Operations shows $286,000 revenue for Q1 2009 versus $0 for Q1 2008. The MD&A clarifies that the assay business was exited in Dec 2008, and the revenue recognized in Q1 2009 relates to the transition or final sales of that segment.
- Expenses: Selling, general, and administrative (SG&A) expenses decreased significantly from $559,000 in Q1 2008 to $139,000 in Q1 2009, driven by reduced non-cash compensation, overhead, and staff reductions.
- Derivative Liabilities: The change in value of warrant and derivative liabilities resulted in an expense of $55,000 in Q1 2009, compared to $395,000 in Q1 2008.
- Cash Position: Cash reserves depleted from $22,000 at the beginning of the quarter to $0 by March 31, 2009.
Outlook, Risks, and Contingencies
- Going Concern: Management states that the current rate of cash usage raises substantial doubt about the Company's ability to continue as a going concern. The Company has an accumulated deficit of over $75 million and zero cash. It is actively seeking equity or debt financing to sustain operations.
- Debt Defaults: The Company is in default on its October 2006 Convertible Debentures ($2.123 million principal) due to missed monthly redemption payments since February 2007. Penalty interest accrues at up to 18% annually. Holders have the right to accelerate repayment and sell collateral.
- Subsequent Financing: Following the quarter end, the Company entered into multiple convertible demand promissory notes with Bristol Investment Fund, Ltd. and others (totaling over $300,000 in principal) and a $2,000,000 convertible debenture financing in October 2009. These instruments include aggressive conversion features (e.g., 60% of lowest trading price) and warrants.
- Internal Controls: The Company disclosed material weaknesses in internal controls, noting that all accounting and financial reporting operations were performed by a single individual.
Investor Verification Checklist
- Cash Runway: Verify the status of the $2,000,000 October 2009 financing and whether funds have been released from escrow to cover operating expenses.
- Debt Settlement: Confirm the status of the default on the 2006 Debentures and the terms of the Standstill and Forbearance Agreement with Bristol Investment Fund.
- Dilution Risk: Assess the potential dilution from the numerous warrants and convertible notes issued in 2009, many of which have conversion prices tied to the lowest trading prices (e.g., $0.01 or 60% of low).
- Revenue Sustainability: Determine if the $286,000 revenue in Q1 2009 was a one-time event related to the asset sale or indicative of ongoing nutraceutical sales.
- Internal Controls: Review any updates regarding the remediation of the material weakness where a single individual controls all financial reporting.